Valuation: PREDILIFE

Market Cap 5.41M 6.26M 6.26M 5.09M 4.62M 8.7M 600M 8.82M 59.67M 23.38M 300M 23.5M 22.99M 999M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 10.18M 11.79M 11.79M 9.58M 8.71M 16.38M 1.13B 16.62M 112M 44.05M 565M 44.27M 43.31M 1.88B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%-3.27%+97.90%+294.86% 3.92B
-3.33%-12.35%+35.28%+64.10% 3.27B
-0.99%+8.32%+181.20%+15.82% 3.18B
-0.43%-2.22%+289.70%+449.11% 2.39B
-1.68%-5.23%-25.35%-27.61% 2.23B
-0.43%-3.67%+9.37% - 1.52B
-5.75%-6.91%+7.83%+44.98% 977M
+1.06%-1.20%+123.35%-43.22% 855M
-11.56%-1.10%+8.62%+270.60% 545M
Average -2.66%-2.48%+80.88%+133.58% 2.1B
Weighted average by Cap. -1.79%-2.54%+97.64%+148.65%

Financials

2024 2025
Net sales 493K 571K 571K 464K 422K 793K 54.71M 805K 5.44M 2.13M 27.36M 2.14M 2.1M 91.15M 836K 968K 968K 786K 715K 1.34M 92.72M 1.36M 9.22M 3.62M 46.37M 3.63M 3.55M 154M
Net income -4.26M -4.94M -4.94M -4.01M -3.65M -6.86M -473M -6.96M -47.07M -18.45M -237M -18.54M -18.14M -788M -3.93M -4.56M -4.56M -3.7M -3.36M -6.33M -436M -6.42M -43.42M -17.02M -218M -17.1M -16.73M -727M
Net Debt 3.54M 4.1M 4.1M 3.33M 3.03M 5.69M 393M 5.77M 39.05M 15.3M 196M 15.38M 15.05M 654M 4.78M 5.53M 5.53M 4.5M 4.09M 7.68M 530M 7.8M 52.73M 20.66M 265M 20.77M 20.32M 883M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-